Trevi Therapeutics to Participate in Upcoming March Conferences

Rhea-AI Summary

Trevi Therapeutics (NASDAQ: TRVI) announced its participation in several upcoming conferences in March 2023. The events include the Frazier/Fenwick Winter Investor Event from March 7-10, the Oppenheimer 33rd Annual Healthcare Conference on March 13-15 with a corporate presentation on March 13 at 4:00 p.m. ET, and BIO-Europe Spring on March 20-22 (in-person) and March 28-30 (virtual). Trevi is focused on Haduvio™ (oral nalbuphine ER) for chronic cough treatment in adults with idiopathic pulmonary fibrosis and prurigo nodularis, reporting positive results from its Phase 2 CANAL trial.

Frazier/Fenwick Winter Investor Event, March 7-10

Oppenheimer 33^rd Annual Healthcare Conference, March 13-15 – Corporate presentation will be held on Monday, March 13, at 4:00 p.m. ET

BIO-Europe Spring, March 20-22

NEW HAVEN, Conn., March 6, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior management will attend and participate in the following March conferences.

Frazier/Fenwick Winter Investor Event
Dates:  March 7-10, 2023

Oppenheimer 33rd Annual Healthcare Conference (March 13-15, 2023)
Presentation Date/Time:  Monday, March 13 at 4:00 p.m. ET
Corporate presentation: Jennifer Good, President and CEO, and Lisa Delfini, CFO

BIO-Europe Spring
Dates: March 20-22, 2023 (in-person) and March 28-30, 2023 (virtual)
Location: Basel, Switzerland and virtual
For more information or to register, please click here.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational oral therapy Haduvio™ (nalbuphine ER) for the treatment of chronic cough in adults with IPF, other chronic cough indications, and for the treatment of prurigo nodularis. The Company reported statistically significant results from the Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in adults with IPF. Based on this positive data, Trevi plans to focus future clinical development on chronic cough conditions, including IPF, refractory chronic cough, and interstitial lung diseases (ILDs).

For more information, visit www.TreviTherapeutics.com and follow the Company on Twitter and LinkedIn.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-march-conferences-301763676.html

SOURCE Trevi Therapeutics, Inc.

FAQ

What conferences will Trevi Therapeutics (TRVI) participate in March 2023?

Trevi Therapeutics will attend the Frazier/Fenwick Winter Investor Event (March 7-10), Oppenheimer 33rd Annual Healthcare Conference (March 13-15), and BIO-Europe Spring (March 20-22 in-person and March 28-30 virtually).

When is Trevi Therapeutics' presentation at the Oppenheimer Healthcare Conference?

Trevi Therapeutics' corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 13, 2023, at 4:00 p.m. ET.

What is Haduvio™ and its significance for Trevi Therapeutics (TRVI)?

Haduvio™ (oral nalbuphine ER) is Trevi Therapeutics' investigational therapy aimed at treating chronic cough related to idiopathic pulmonary fibrosis and prurigo nodularis.

What were the results of Trevi Therapeutics' Phase 2 CANAL trial?

Trevi Therapeutics reported statistically significant results from the Phase 2 CANAL trial, reinforcing their focus on developing treatments for chronic cough conditions.